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Nowadays, the “nonspecific resistance of the body” con-
cept is fundamental when relating to the intimate molecular 
mechanisms of the development of the body’s primary respon-
se to the harmful actions of various pathogens such as bacteria, 
viruses, fungi, etc.  In mammals, the nonspecific resistance 
is directly involved in the activation and subsequent orienta-
tion of the adaptive immune response.  Thus, a unique body 
protection system against various pathogens is generated.
The innate immunity mechanism has been preserved 
throughout the evolution, its function being quick and effi-
cient fight against the pathogens penetrating the body.  The 
nonspecific immune protection system primarily does not 
recognize the individual antigens specific to certain patho-
gens, but it recognizes a string of common structures charac-
teristic of many representatives of a group of such organisms. 
This type of recognition is based on a limited set of specific 
membrane receptors, which have been called molecular ‘pat-
tern recognition receptors’ (PRRs) that recognize pathogen 
associated molecular patterns (PAMPs).  The discovery of 
the PRRs, involved in the production and development of 
the body response reaction to the pathogen invasion, is one 
of the latest, fundamental achievements [2].  The presence of 
PRRs is a proof of the structural and metabolic “economy” 
principle, which is characteristic of living organisms.  Thus, 
the mammalian cells, possessing a limited number of receptors 
with a defined area of recognition, may specifically appre-
hend and bind a significantly higher number of pathogens 
due to the ability of recognizing joint molecular patterns of 
their antigens.  As a result, the spectrum and the number of 
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Abstract
The study results of the last 10-12 years have established that the activity of the nonspecific immunological protection system is based on a limited 
set of specific membrane receptors, which have been called molecular ‘pattern recognition receptors’ (PRRs) that recognize pathogen associated mo-
lecular patterns (PAMPs).  After the detection of PAMPs PRRs trigger an inflammatory response that leads to the destruction of pathogens.  Toll-like 
receptors (TLRs) refer to PRRs, along with three other families:  NOD-Like receptors, RIG-I-Like receptors and C-type Lectin receptors.  In humans, 
TLRs are present on dendritic cells, macrophages, neutrophils, B-lymphocytes, mast cells, enterocytes, some cells of the central nervous system (as-
trocytes), hepatocytes, etc.  The attempts have been made in order to obtain vaccines against microbes, as well as the vaccines designed to trigger or 
enhance an anti-tumor immune response by stimulating the TLRs and other similar receptors.  The suppression or enhancement of TLRs activity is an 
important pathogenic mechanism, underlying many infectious or immunological diseases (including autoimmune).  These mechanisms can be used 
for the further elaboration of new methods and algorithms for prevention, diagnosis and treatment of the mentioned diseases.  Thus, not only strong 
fundamental data on the mechanisms of the innate immunity have been accumulated and the attempts to apply these results have been made, but also 
it has been managed to integrate the non-specific immunity mechanisms with the adaptive immunity and to found a new field in immunology - an 
integrated immunology, which creates the background for new therapeutic, diagnostic and preventive strategies in the future.
Key words: toll-like receptors, molecular pattern, pathogens.
the pathogens, against which the cell and the whole body are 
protected, significantly increases, such a major response being 
achieved with the relatively modest resources.
Substances with different structures, properties and origin, 
such as lipopolysaccharides (LPS) of gram-negative bacteria, 
peptidoglycan (PGN) of gram-positive bacteria, double-stran-
ded RNA (dsRNA) of viruses, β-glycans of fungi and others 
refer to typical PAMPs.  These structures are found in germs 
(bacteria, viruses, fungi, parasites), but not in mammals. 
After their detection, PRRs trigger an inflammatory response 
leading to the destruction of the pathogens.
The Toll-like receptors (TLRs) belong to the PRRs category 
that initiates a pro-inflammatory signaling pathway together 
with the other three categories of PRRs – NOD-Like receptors, 
RIG-I-Like receptors and C-type Lectin receptors.  The TLRs 
family comprises a significant number of phylogenetically 
related proteins present in both vertebrates and invertebrates. 
TLRs, specific to the organisms that are at various stages of 
evolutionary development, show both similarities and di-
fferences in the structure, conformation and properties that 
determine the peculiarities of their activation mechanisms and 
the accomplishment of the specific intracellular response [17].
The Toll-like receptors are named so because of the si-
milarity to the protein encoded by the Toll gene present in 
Drosophila. Jules Hoffmann (Nobel Prize, 2011) has proved 
that the Toll gene does not only control the dorso-ventral 
pattern during embryogenic development of Drosophila but 
is also involved in the immune defense of the fly.  The protein 
produced by the Toll gene is an important transmembrane 
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receptor for the antifungal immunity of the adult Drosophila 
without which it can not survive a fungal infection [13, 14, 19].
Currently about 15 different forms of TLRs are attested. 
In humans, this type of receptors is found on dendritic cells, 
macrophages, neutrophils, B-lymphocytes, mast cells, ente-
rocytes, cells of the central nervous system (astrocytes), he-
patocytes, etc.  Some cells are characterized by an individual 
set of TLRs, which determines the specific response of the 
cell to the activation of this set of receptors.  Thus, TLR1 is 
expressed in all types of leukocytes, including monocytes, 
polymorphonuclear leukocytes, T and B lymphocytes and NK 
cells; TLR2, TLR4 and TLR5 are found on cell membranes of 
the monocytic series; TLR3 is found in human dendritic cells, 
etc. [16]. The area of cellular distribution of TLRs allowed 
their division by the following categories:
1. Ubiquitous or pervasive in most of the cells (TLR1).
2. Restricted to a limited number of cells (TLR2, TLR4 
and TLR5).
3. Specific for a particular type of cells (TLR3) [15] (fig. 1).
All the representatives of the TLRs family are transmem-
brane proteins of type 1 that possess two common structural 
domains for all individual TLRs crucial for the achievement of 
their functions: the extracellular domain (N-teminal) contai-
ning repetitive sequences rich in leucine (leucine-rich repeti-
tive domain), a single transmembrane helix and cytoplasmic 
domain (C-terminal) – TIR (Toll/IL-1 receptor), similar to the 
cytoplasmic domain of the receptor family for IL-1.
The above mentioned structural elements are directly 
involved in the recognition and binding of specific PAMPs, 
and in the transfer of information within the cell with the 
induction of the immune and metabolic responses [8, 15].
Fig. 1.  The generic structure of TLRs.   
(http://www.invivogen.com/review-tlr).
The TLRs family members are able to recognize certain 
pathogens and to orchestrate a corresponding response of 
the nonspecific and adaptive immunity due to the capacity of 
identifying PAMPs common to various microorganisms that 
invade the human body.  The lipoproteins with triacylated 
N-terminal cysteine are recognized by TLR1, which forms a 
heterodimer with TLR2, whereas diacylated lipoproteins are 
recognized by TLR6 in cooperation with TLR4; the double-
stranded RNA specific to viruses is recognized by TLR3; TLR4 
may specifically bind lipopolysaccharide; TLR5 recognizes 
flagellin; the members of TLR7-TLR9 subfamily recognize 
viral or bacterial single-stranded RNA, as well as compounds 
with cyclic elements in their structures, such as the heme or 
the nucleic acids (CpG sequences of the bacterial DNA) (tab. 
1) [10, 17].  Despite the wide variety of ligands recognized by 
the TLRs, all receptors have leucine-rich repetitive regions 
and after the binding of the ligand, the extracellular domains 
form a dimmer in the form of „m”.
The TLRs studies have established two features of the li-
gand recognition mechanism, which allow the identification 
of a significantly large number of ligands by a relatively limited 
number of Toll-like receptors.
Some TLRs possess the ability to recognize the same 
structural pattern, common to many pathogens, which the 
latter cannot modify easily and quickly.
The same TLRs can recognize several common structural 
patterns of the pathogen.  For example, TLR4 recognizes not 
only lipopolysaccharides, but also a number of viral glyco-
proteins.
Recent studies have revealed the existence of the endoge-
nous ligands of TLRs.  The heat shock proteins (HSPs) physi-
ologically involved in the folding, assembly and the transport 
of proteins are produced in increased amounts in stressful 
situations.  Some specific forms of HSPs - HSP60 and HSP70, 
eliminated by the necrotized cells, activate the inflammatory 
process with the help of TLRs.  The TLR4 induces tissue da-
mage, the inflammatory process being activated by HMBG1 
(high mobility group 1) – a nuclear protein, released by cells in 
the terminal stage of apoptosis.  During traumatic processes, 
many proteolytic and glycolytic enzymes are released in the 
tissues, which cleave the extracellular matrix components 
into heparansulfat, hyaluronic acid, the domain A fibronectin 
and biglican, which, in turn, activate the TLRs and induce a 
non-specific immune response. Now it is established that the 
TLRs are activated by the following endogenous ligands: 1. 
TLR2 - HSP60, HSP70, 96 Da glycoprotein of the endoplas-
mic reticulum, minimally modified LDL, HMBG1, 2. TLR3 
- mRNA, 3. TLR4 - HSP60, HSP70, Gp96, fibronectin, heparan 
sulfate, oligosaccharides of hyaluronic acid, the protein A of 
surfactant, HMBG1, 4. TLR7 - mRNA, 5. TLR9 - DNA, the 
chromatin-IgG complexes [16].
Activation of TLRs triggers several intracellular signaling 
pathways.  Te intracellular TIR domain (Toll/IL-1 receptor) is 
essential for the intracellular translation of the signal.  After 
the detection of PAMPs, TLRs form dimmers and/or associate 
with other receptors or molecules that determine the interacti-
on of the TIR domain with the intracellular adapter molecules. 
At the moment, scientists recognize the adapter functions of 
four molecules: 1. MyD88 (myeloid differentiation factor 88), 
2. the inductor adapter of IFN-β containing the TIR domain 
(TRIF or TICAM1), 3. the adapter protein similar to MyD88 
(TIRAP or MAL protein) and (4) the adapter molecule related 
to TRIF (TRAM or TICAM2).  MyD88 and TRIF mediate two 
signaling pathways known as the MyD88-dependent pathway 
REsEARcH stUDiEs , October 2013, Vol. 56, No 5
and the TRIF-dependent pathway.  TIRAP and TRAM func-
tion as contact molecules with the TIRA and TRAM proteins 
that link MyD88 to TLR2 and TLR4 and TRIF to TLR4 [11, 
20].  The adapter molecules induce successive activation cas-
cades of different members of the kinase family, associated to 
the IL-1 receptor (IRAK – IL-1 receptor associated kinase).
These events end with the activation of the transcription 
factors NF-kB, Jun, Fos and others and the production of a 
Table 1
The Toll-like receptors and the variety of ligands recognized by them (Wikipedia)
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number of cytokines.  An important role among cytokines, 
the synthesis of which is induced by the activation of TLRs, 
is played by the pro-inflammatory interleukins – IL-1, IL-6, 
IL-8, FNO-α, IL-12 and others, which regulate the systemic 
inflammatory response that precedes the adaptive immune 
responses.  The set of produced cytokines is determined by 
the type of activated TLR.  Thus, TLR4 triggers the synthesis 
of IL-1, IL-6 and IL-8, while TLR2 triggers the synthesis of 
IL-12 and TNF-α.
The synthesized cytokines induce the rapid development 
of the non-specific immune response and coordinate the 
initiation of the adaptive response through multiple mecha-
nisms – IL-1 activates the immunocompetent cells in the 
inflammatory site and stimulates the production of other 
proinflammatory cytokines, IL-8 amplifies the neutrophils’ 
chemotaxis, increases their activity and adhesion capacity as 
well as the enzyme release, IL-6 is the main regulator of the 
B-lymphocytes transformation into plasmocytes, IL-12 is 
the stimulator of NK cells, etc.  In addition to inflammatory 
cytokines, as a result of TLRs activation by microbial products, 
antimicrobial effector molecules are formed, for example, 
nitric oxide synthases.  Thus, the TLRs and the intracellular 
cascades, induced by them, are an integral, crucial part of the 
protection mechanisms of the immunological adaptation of 
organisms, including the human ones, coexisting with nume-
rous microorganisms.
Stimulation of Toll-like receptors, expressed on the cell 
membrane, as well as in the cytoplasm and on the lysosomal 
membranes of dendritic cells, triggers the receptors’ matura-
tion, resulting in the synthesis of co-stimulatory molecules 
and in the increase of the capacity of antigen presence in 
these cells.  Although the dendritic cells play a crucial role 
in the induction of the acquired immunity, the acquired 
immune response is initiated at the level of receptors with 
great phylogenetic prevalence of the innate immune system 
[9].  The pathogen recognition by the Toll-like receptors 
helps the specific targeting of the acquired immune system 
(involving specific B and T lymphocytes), finally leading to 
the elimination of the pathogen.
The complexity of the dendritic cell activation process is 
enhanced by the fact that there are multiple populations of 
dendritic cells, different by location, function and phenotype. 
Dendritic cells differ greatly by the types of expressed Toll-
like receptors and, therefore, differ by the type of detected 
pathogens and the type of immune response that the receptors 
can initiate.
At the same time, the halting or the amplification of the 
TLRs activity is an important aspect of the pathogenetic 
mechanisms underlying many infectious or immunological 
diseases.  Thus, it has been established that  the persons with 
the diminished activity of the TLR4 receptors are five times 
more susceptible to the development of serious bacterial infec-
tions, compared to those with normal expression of the same 
receptor.  However, the hyperexpression of TLR4 represents 
a favourable background for an exagerated protective reacti-
on and the development of a severe systemic inflammatory 
response in people with sepsis.
After the discovery of the first Toll-like receptors in 1997, 
the understanding of the molecular bases of the innate immu-
nity has been significantly improved [9].  The TLR family and 
their signaling pathways have been analyzed in great detail. 
To date, there is a significant evidence of the TLR involvement 
in such inflammatory and immune diseases as rheumatoid 
arthritis, diabetes, allergies/asthma and atherosclerosis [12]. 
The latest studies attest the involvement of TLRs in the di-
seases with an autoimmune pathogenetic element, caused by 
TLRs inappropriate activation by endogenous ligands, as a 
result, a ”sterile” autoimmune inflammation is developped. 
The endogenous activation of TLR7 and TLR9 by certan RNA 
and DNA is one of the mechanisms of the lupus and psoriasis 
development.  TLR2, TLR4 and MyD88 are the promoters 
of the renal transplant rejection [4].  The mutation or the 
deficiency of TLR4 and TLR2 affects the LDL metabolism 
and modifies or damages the LDL forms, which favours the 
emergence and the development of atherosclerosis and car-
diovascular diseases [6].
The results of TLRs research have allowed the formation 
of a theoretical foundation and the elaboration of new phar-
macotherapeutical remedies (with a low molecular mass and 
nucleic acid-based), whose mechanism of action is based on 
the specific activation or inhibition of these receptors [1, 10]. 
Two types of medications at the stage of clinical trials have 
been proposed.
1. The agonists of TLRs - apropriate for the treatment of 
the diseases accompanied by immunodeficiency.
2. The antagonists of TLRs - immunosuppressant 
remedies used in the therapy of immunoinflammatory 
pathologies.
The contemporary data about the nature of nonspecific 
immunity and the role of TLRs in its operating mechanisms 
allowed us to suppose that the activation of this segment of 
the immune system via PAMPs carrying drugs can form a 
rapid and non-specific defense against a large number of 
pathogens.  Modern vaccines that are elaborated on the base 
of this concept would be able to induce a rapid and effective 
protection reaction against microorganisms that are resistant 
to traditional antibacterial drugs [5, 18].  On the base of the 
purification of the viral protein that inactivates TLRs the vacci-
nes against the hepatitis B virus (HBV), the human papilloma 
virus, the herpes simplex virus, the respiratory syncytial virus 
and the Epstein-Barr virus have been tested.
The ongoing research in this field is expected to improve 
not only the vaccines against microbes, but the vaccines desig-
ned to trigger or to improve the anti-tumor immune responses 
as well.  The progress in this area depends both on the better 
use of adjuvants designed to enhance the innate immunity by 
stimulating the Toll-like receptors and other similar receptors 
and the methods for the transformation of the dendritic cells 
into the cells that contain a sufficient  amount of antigens [7].
Another type of progress concerning a clinical application 
is expected to be achieved in the domain of the autoimmune 
and the inflammatory diseases treatment.  For example, the 
promising results have been obtained, with the help of animal 
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models of inflammatory diseases, both by interfering with the 
innate immunity through the blocking the TLRs and by inhi-
biting the immune response associated to the illness caused 
by the manipulation of dendritic cells.
The contemporary data regarding the role of Toll-receptors 
in the formation of the immune response, significantly facili-
tate the understanding of the mechanisms of the emergence 
of allergic, autoimmune, neoplastic, polyetiologic infectious 
and inflammatory endogenous conditions.  These data create 
the theoretical foundation necessary for further elaboration 
of new methods and algorithms for prevention, diagnosis and 
treatment, based on the knowledge of the structure, properties, 
functions and location of TLRs [3].
In conclusion, based on the results of the studies during 
the last 10-12 years, we can state that the nonspecific immu-
nological protection system is based on a limited set of spe-
cific membrane receptors, which have been called molecular 
‘pattern recognition receptors’ (PRRs), which also include the 
Toll-like receptors – TLRs, that recognize pathogen-associated 
molecular patterns (PAMPs).  The recognition of pathogens 
by Toll-like receptors helps the acquired immune system to 
find a target (involving specific B and T lymphocytes) and 
ultimately to eliminate the pathogen.  The TLRs are involved in 
the pathogenesis of the inflammatory, immune, autoimmune 
and neoplasic diseases.  The study of the TLRs has allowed 
the formation of a theoretical foundation and the elaboration 
of new pharmacotherapeutical remedies, whose mechanism 
of action is based on the specific activation or inhibition of 
the TLRs.
Thus, the scientists have accumulated not only conclusive 
fundamental data about the nonspecific immunity mecha-
nisms and made attempts to practically apply the results, but 
they have also managed to integrate the nonspecific immu-
nity mechanisms with those of the adaptive immunity, thus, 
forming a base for the substantiation of the new branch in 
immunology – the integral immunology, which creates the 
prerequisites for the inauguration of new therapeutic, dia-
gnostic and prophylactic strategies in the future.
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